However, oncogenic KRAS promotes tumor cell immune escape and immune therapy resistance through attracting immune-suppressive cells or suppressing cytotoxic cells in a colorectal cancer mouse model [61, 62]. This evidence concerns the gene KRAS and colorectal cancer.